Display options
Cite
Ndombi EM, Budambula V, Webale MK, et al. Serum adiponectin in HIV-1 and hepatitis C virus mono- and co-infected Kenyan injection drug users. Endocr Connect. 2015;4(4):223-32doi: 10.1530/EC-15-0071.
Ndombi, E. M., Budambula, V., Webale, M. K., Musumba, F. O., Wesongah, J. O., Mibei, E., Ahmed, A. A., Lihana, R., & Were, T. (2015). Serum adiponectin in HIV-1 and hepatitis C virus mono- and co-infected Kenyan injection drug users. Endocrine connections, 4(4), 223-32. https://doi.org/10.1530/EC-15-0071
Ndombi, Eric M, et al. "Serum adiponectin in HIV-1 and hepatitis C virus mono- and co-infected Kenyan injection drug users." Endocrine connections vol. 4,4 (2015): 223-32. doi: https://doi.org/10.1530/EC-15-0071
Ndombi EM, Budambula V, Webale MK, Musumba FO, Wesongah JO, Mibei E, Ahmed AA, Lihana R, Were T. Serum adiponectin in HIV-1 and hepatitis C virus mono- and co-infected Kenyan injection drug users. Endocr Connect. 2015 Dec;4(4):223-32. doi: 10.1530/EC-15-0071. Epub 2015 Aug 25. PMID: 26306727; PMCID: PMC4566843.
Copy Download .nbib Format: NLM
Share it on

Endocr Connect. 2015 Dec;4(4):223-32. doi: 10.1530/EC-15-0071. Epub 2015 Aug 25.

Serum adiponectin in HIV-1 and hepatitis C virus mono- and co-infected Kenyan injection drug users.

Endocrine connections

Eric M Ndombi, Valentine Budambula, Mark K Webale, Francis O Musumba, Jesca O Wesongah, Erick Mibei, Aabid A Ahmed, Raphael Lihana, Tom Were

Affiliations

  1. Bomu HospitalMombasa, KenyaDepartment of PathologyKenyatta University, Nairobi, KenyaDepartment of Environment and Health SciencesTechnical University of Mombasa, Mombasa, KenyaDepartment of Biomedical Sciences and TechnologyMaseno University, Maseno, KenyaDepartment of Medical Laboratory SciencesJomo Kenyatta University of Agriculture and Technology, Juja, KenyaKapkatet CampusUniversity of Kabianga, Kericho, KenyaCentre for Virus ResearchKenya Medical Research Institute, Nairobi, KenyaDepartment of Medical Laboratory SciencesMasinde Muliro University of Science and Technology, Post Box 190-50100 Kakamega, Kenya.
  2. Bomu HospitalMombasa, KenyaDepartment of PathologyKenyatta University, Nairobi, KenyaDepartment of Environment and Health SciencesTechnical University of Mombasa, Mombasa, KenyaDepartment of Biomedical Sciences and TechnologyMaseno University, Maseno, KenyaDepartment of Medical Laboratory SciencesJomo Kenyatta University of Agriculture and Technology, Juja, KenyaKapkatet CampusUniversity of Kabianga, Kericho, KenyaCentre for Virus ResearchKenya Medical Research Institute, Nairobi, KenyaDepartment of Medical Laboratory SciencesMasinde Muliro University of Science and Technology, Post Box 190-50100 Kakamega, Kenya [email protected].

PMID: 26306727 PMCID: PMC4566843 DOI: 10.1530/EC-15-0071

Abstract

Adiponectin is an important marker of anthropometric profiles of adipose tissue. However, association of adiponectin and adiposity in HIV mono- and co-infected and hepatitis (HCV) injection drug users (IDUs) has not been elucidated. Therefore, the relationship of total adiponectin levels with anthropometric indices of adiposity was examined in HIV mono-infected (anti-retroviral treatment, ART-naive, n=16 and -experienced, n=34); HCV mono-infected, n=36; HIV and HCV co-infected (ART-naive, n=5 and -experienced, n=13); uninfected, n=19 IDUs; and healthy controls, n=16 from coastal Kenya. Anthropometric indices of adiposity were recorded and total circulating adiponectin levels were measured in serum samples using enzyme-linked immunosorbent assay. Adiponectin levels differed significantly amongst the study groups (P<0.0001). Post-hoc analyses revealed decreased levels in HIV mono-infected ART-naive IDUs in comparison to uninfected IDUs (P<0.05) and healthy controls (P<0.05). However, adiponectin levels were elevated in HCV mono-infected IDUs relative to HIV mono-infected ART-naive (P<0.001) and -experienced (P<0.001) as well as HIV and HCV co-infected ART-naive (P<0.05) IDUs. Furthermore, adiponectin correlated with weight (ρ=0.687; P=0.003) and BMI (ρ=0.598; P=0.014) in HIV mono-infected ART-naive IDUs; waist circumference (ρ=-0.626; P<0.0001), hip (ρ=-0.561; P=0.001) circumference, and bust-to-waist ratio (ρ=0.561; P=0.001) in HIV mono-infected ART-experienced IDUs; waist girth (ρ=0.375; P=0.024) in HCV mono-infected IDUs; and waist-to-hip ratio (ρ=-0.872; P=0.048) in HIV and HCV co-infected ART-naive IDUs. Altogether, these results suggest suppression of adiponectin production in treatment-naive HIV mono-infected IDUs and that circulating adiponectin is a useful surrogate marker of altered adiposity in treatment-naive and -experienced HIV and HCV mono- and co-infected IDUs.

© 2015 The authors.

Keywords: HIV; adiponectin; anthropometric markers of adiposity; anti-retroviral treatment; hepatitis C virus; injection drug users

References

  1. Drug Alcohol Depend. 2011 Oct 1;118(1):73-7 - PubMed
  2. Am J Drug Alcohol Abuse. 2010 Jan;36(1):78-86 - PubMed
  3. J Viral Hepat. 2011 Jul;18(7):e307-14 - PubMed
  4. Eur J Endocrinol. 2002 Aug;147(2):173-80 - PubMed
  5. Lancet. 2011 Aug 13;378(9791):571-83 - PubMed
  6. J Clin Endocrinol Metab. 2003 Apr;88(4):1559-64 - PubMed
  7. J Endocrinol Invest. 2014 Jun;37(6):533-9 - PubMed
  8. Eur J Endocrinol. 2014 Nov;171(5):545-54 - PubMed
  9. Obesity (Silver Spring). 2014 May;22(5):1345-50 - PubMed
  10. Eur J Endocrinol. 2007 Aug;157(2):181-8 - PubMed
  11. Biochimie. 2012 Oct;94(10):2082-8 - PubMed
  12. Obesity (Silver Spring). 2010 Nov;18(11):2077-85 - PubMed
  13. Cardiovasc Diabetol. 2007 Oct 16;6:31 - PubMed
  14. Ann Hum Biol. 2011 May;38(3):247-56 - PubMed
  15. World J Hepatol. 2013 Feb 27;5(2):74-81 - PubMed
  16. BMC Clin Pathol. 2014 Dec 16;14(1):46 - PubMed
  17. Ethiop J Health Sci. 2014 Jul;24(3):243-52 - PubMed
  18. Psychiatry Res. 2013 Dec 15;210(2):536-40 - PubMed
  19. AIDS Res Hum Retroviruses. 2013 May;29(5):761-8 - PubMed
  20. J Gastroenterol Hepatol. 2009 Apr;24(4):558-63 - PubMed
  21. Pharmacol Res Commun. 1980 Oct;12(9):855-61 - PubMed
  22. J Clin Endocrinol Metab. 2003 Apr;88(4):1907-10 - PubMed
  23. BMC Res Notes. 2014 Apr 03;7:207 - PubMed
  24. Int J High Risk Behav Addict. 2013 Dec;2(3):117-21 - PubMed
  25. Hepatology. 2008 Aug;48(2):374-84 - PubMed
  26. Antivir Ther. 2006;11(6):729-40 - PubMed
  27. J Neuroimmune Pharmacol. 2015 Mar;10(1):102-10 - PubMed
  28. Trends Endocrinol Metab. 2010 Jan;21(1):33-40 - PubMed
  29. Metabolism. 2006 Jul;55(7):940-5 - PubMed
  30. J Clin Endocrinol Metab. 2003 Feb;88(2):627-36 - PubMed
  31. Ann Nutr Metab. 2009;55(4):351-7 - PubMed
  32. Cytokine. 2012 May;58(2):253-60 - PubMed
  33. J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):283-90 - PubMed
  34. BMC Infect Dis. 2014 Jun 23;14:347 - PubMed
  35. Hypertension. 2005 Jun;45(6):1094-100 - PubMed
  36. AIDS Res Treat. 2011;2011:890308 - PubMed
  37. Diabetes Care. 2007 Jan;30(1):113-9 - PubMed
  38. Diabetes Care. 2013 Aug;36(8):2415-22 - PubMed
  39. J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):323-30 - PubMed
  40. J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):371-8 - PubMed
  41. FASEB J. 2002 Aug;16(10):1254-6 - PubMed
  42. Public Health Nutr. 2004 Oct;7(7):863-70 - PubMed
  43. AIDS Rev. 2013 Jan-Mar;15(1):25-31 - PubMed
  44. Diabetologia. 2006 Mar;49(3):538-42 - PubMed
  45. Physiol Res. 2005;54(1):73-8 - PubMed
  46. AIDS Behav. 2015 Jun;19(6):1089-97 - PubMed
  47. HIV Med. 2006 May;7(4):268-74 - PubMed
  48. AIDS. 2003 Jul 4;17(10):1503-11 - PubMed
  49. Antivir Ther. 2003 Feb;8(1):9-15 - PubMed
  50. Exp Diabetes Res. 2012;2012:103063 - PubMed
  51. Clin Cornerstone. 2006;8 Suppl 4:S7-S13 - PubMed
  52. Lancet. 2008 Nov 15;372(9651):1733-45 - PubMed
  53. Cytokine. 2013 Oct;64(1):97-102 - PubMed
  54. Eur J Clin Invest. 2014 May;44(5):453-62 - PubMed
  55. BMC Clin Pathol. 2014 Jul 09;14:32 - PubMed

Publication Types